Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab (NASDAQ: IMAB), now known as NovaBridge Biosciences, generates a steady flow of news as a U.S.-based, global biotech company focused on precision immuno-oncology. Investors following IMAB-related headlines can track how the company advances its lead Claudin 18.2 x 4-1BB bispecific antibody, givastomig, and other pipeline assets through clinical milestones, strategic transactions, and capital markets activity.
News coverage commonly highlights clinical data from Phase 1 and Phase 1b studies of givastomig in Claudin 18.2-positive gastric and gastroesophageal cancers, including monotherapy results and combination regimens with immunochemotherapy in the first-line metastatic setting. Company announcements describe objective response rates, safety findings, and study design details from presentations at major oncology conferences such as ESMO GI and the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting.
Beyond clinical readouts, IMAB news items also cover the company’s broader transformation into a global biotech platform under the NovaBridge Biosciences name. Releases discuss the adoption of a hub-and-spoke business model, the formation of subsidiaries like Visara, Inc. for VIS-101 in ophthalmology, and strategic agreements with partners including ABL Bio, AffaMed Therapeutics, AskGene Pharma, and Everest Medicines. Capital markets updates, such as underwritten offerings of American Depositary Shares and intentions to pursue a dual listing on the Hong Kong Stock Exchange, are also key themes.
On this news page, readers can review company press releases, SEC-referenced announcements, and other IMAB-related updates in one place. For investors and researchers, regularly checking this feed offers insight into clinical progress, partnership activity, governance changes, and financing events that shape the outlook for I-Mab’s, and NovaBridge Biosciences’, oncology and ophthalmology programs.
I-Mab (Nasdaq: IMAB) announced the dosing of the first patient in a Phase 1b clinical trial for plonmarlimab (TJM2), targeting rheumatoid arthritis (RA) in China. This multi-center, double-blind, placebo-controlled study will involve 63 patients over eight weeks, assessing safety and efficacy. Plonmarlimab, a humanized IgG1 antibody, neutralizes GM-CSF to potentially reduce inflammation in RA. The company aims to establish proof of concept for RA and plans to explore broader autoimmune applications, marking a significant step in its pipeline development.
I-Mab (Nasdaq: IMAB) announced it will report financial results for the six months ended June 30, 2020, before the market opens on August 31, 2020. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss these results and provide a corporate update. I-Mab, a clinical-stage biopharmaceutical company, focuses on developing novel biologics for immuno-oncology and autoimmune diseases, aiming to bring transformational medicines to patients through innovation. The company's innovative pipeline includes over 10 drug candidates at various stages.
I-Mab (Nasdaq: IMAB) announced the acceptance of its pivotal trial application for eftansomatropin (TJ101) by the China National Medical Products Administration. This innovative long-acting recombinant human growth hormone aims to treat pediatric growth hormone deficiency (PGHD). The Phase 3 trial will enroll approximately 165 subjects, comparing eftansomatropin with the daily treatment Norditropin. Preliminary trials indicate that eftansomatropin is well-tolerated and effective, addressing a significant unmet medical need in China, where PGHD affects around 3.4 million patients.
I-Mab (Nasdaq: IMAB) announced the appointment of Ivan Yifei Zhu as Chief Commercial Officer, effective August 10, 2020. Zhu aims to enhance I-Mab's commercialization strategies and infrastructure, preparing for impending product launches. With over 20 years of experience in global and domestic pharmaceutical firms, he has successfully led product launches, including China's first domestic biosimilar of bevacizumab. This appointment marks a significant step for I-Mab, as the company transitions towards becoming a fully integrated global biopharmaceutical entity.
I-Mab (Nasdaq: IMAB) has authorized a stock repurchase program of up to US$20 million for its ordinary shares. This initiative reflects the company's confidence in its pipeline and commitment to enhancing long-term shareholder value. The buyback will be subject to market conditions and executed in accordance with regulatory guidelines. Repurchases can be made over the next 12 months, depending on various factors, including market pricing and capital availability.
Summary not available.
Summary not available.